Search company, investor...

MIGENIX

migenix.com

Stage

Other Investors | Alive

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada.

Headquarters Location

102 - 2389 Health Sciences Mall

Vancouver, British Columbia, V6T 1Z3,

Canada

604-221-9666

Missing: MIGENIX's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MIGENIX's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

MIGENIX Patents

MIGENIX has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/10/2007

5/4/2010

Diseases of liver, Hepatology, HIV/AIDS, Infectious causes of cancer, Virology

Grant

Application Date

7/10/2007

Grant Date

5/4/2010

Title

Related Topics

Diseases of liver, Hepatology, HIV/AIDS, Infectious causes of cancer, Virology

Status

Grant

MIGENIX Frequently Asked Questions (FAQ)

  • Where is MIGENIX's headquarters?

    MIGENIX's headquarters is located at 102 - 2389 Health Sciences Mall, Vancouver.

  • What is MIGENIX's latest funding round?

    MIGENIX's latest funding round is Other Investors.

  • Who are the investors of MIGENIX?

    Investors of MIGENIX include Domain Associates.

  • Who are MIGENIX's competitors?

    Competitors of MIGENIX include Inhibikase Therapeutics, Intarcia Therapeutics, TxCell, Profectus BioSciences, Actinobac Biomed, Crown Bioscience, Altor BioScience, Alfama, Midway Biome, Trius Therapeutics and 17 more.

Compare MIGENIX to Competitors

P
Photothera

Photothere is developing a therapy called NeuroThera, for the treatment of ischemic stroke.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

C
Cardeon Corporation

Cardeon Corporation is engaged in developing solutions for stroke prevention

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

I
Institute for OneWorld Health

A No-profit/no-loss Pharmaceutical Company Targeting Five Diseases In Need Of Drug Development. The company's First Drug, Paromomycin, Is A Treatment For Visceral Leishmaniasis Which Is An Illness Impacting The World's Poorest And Spread By Sand Flies. nnIt's Next Focus Is Malaria Where It Aims To Create And Market Semisynthetic Artemisinin. This Is A Key Malaria Battling Ingredient Which Is In Short Supply.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.